Effect of Gross Total Resection in World Health Organization Grade II Astrocytomas: SEER-Based Survival Analysis
- PMID: 28419878
- DOI: 10.1016/j.wneu.2017.03.140
Effect of Gross Total Resection in World Health Organization Grade II Astrocytomas: SEER-Based Survival Analysis
Abstract
Introduction: We sought to compare the survival benefit associated with gross total resection (GTR) in World Health Organization grade II astrocytomas (A2) with those of grade III (A3) and grade IV (glioblastoma) astrocytomas.
Methods: Using the Surveillance, Epidemiology, and End Results program database (1999-2010), we identified 4113 A2 patients. Surgical resection was defined as GTR, subtotal resection (STR), or no resection. Kaplan-Meier and multivariate Cox proportional hazards analyses were used to assess survival with respect to extent of resection. Results were compared with the benefit of GTR over STR in 2755 A3 and 21,962 glioblastoma patients from the same database.
Results: A multivariate Cox proportional hazards analysis indicated that A2 patients who underwent a GTR had a 28.3% reduction in the hazard of death relative to A2 patients who underwent STR. Similar risk reductions were observed in A2 patients age <50 and ≥50. However, because of differences in the natural history of these cohorts, the relative hazard reduction translated into distinct overall survival profiles. For A2 patients ≥50 years old, the GTR-associated survival benefit was approximately 6 months, resembling that observed in glioblastoma patients. In contrast, GTR in A2 patients <50 years old was associated with survival profiles superior to those observed in A3 patients.
Conclusions: In the Surveillance, Epidemiology, and End Results (SEER) program database, GTR-associated survival benefit in A2 patients ≥50 years old resembled that observed in glioblastoma, while GTR in A2 patients <50 years old was associated with a distinctly more favorable survival profile.
Keywords: Diffuse astrocytoma; Gross total resection; WHO grade II astrocytoma.
Copyright © 2017 Elsevier Inc. All rights reserved.
Similar articles
-
Superior Efficacy of Gross Total Resection in Anaplastic Astrocytoma Patients Relative to Glioblastoma Patients.World Neurosurg. 2016 Jun;90:186-193. doi: 10.1016/j.wneu.2016.02.078. Epub 2016 Feb 24. World Neurosurg. 2016. PMID: 26924115
-
Oligodendroglioma resection: a Surveillance, Epidemiology, and End Results (SEER) analysis.J Neurosurg. 2018 Apr;128(4):1076-1083. doi: 10.3171/2016.11.JNS161974. Epub 2017 May 12. J Neurosurg. 2018. PMID: 28498059
-
Interaction Between the Contributions of Tumor Location, Tumor Grade, and Patient Age to the Survival Benefit Associated with Gross Total Resection.World Neurosurg. 2018 Mar;111:e790-e798. doi: 10.1016/j.wneu.2017.12.165. Epub 2018 Jan 5. World Neurosurg. 2018. PMID: 29309983
-
Surgical outcomes of pediatric spinal cord astrocytomas: systematic review and meta-analysis.J Neurosurg Pediatr. 2018 Oct;22(4):404-410. doi: 10.3171/2018.4.PEDS17587. Epub 2018 Jul 20. J Neurosurg Pediatr. 2018. PMID: 30028275
-
Survival trends of oligodendroglial tumor patients and associated clinical practice patterns: a SEER-based analysis.J Neurooncol. 2017 May;133(1):173-181. doi: 10.1007/s11060-017-2430-z. Epub 2017 Apr 24. J Neurooncol. 2017. PMID: 28439777 Review.
Cited by
-
The Misclassification of Diffuse Gliomas: Rates and Outcomes.Clin Cancer Res. 2019 Apr 15;25(8):2656-2663. doi: 10.1158/1078-0432.CCR-18-3101. Epub 2019 Jan 11. Clin Cancer Res. 2019. PMID: 30635340 Free PMC article.
-
Extent of resection and survival for oligodendroglioma: a U.S. population-based study.J Neurooncol. 2019 Sep;144(3):591-601. doi: 10.1007/s11060-019-03261-5. Epub 2019 Aug 12. J Neurooncol. 2019. PMID: 31407129
-
Increased incidence of second primary malignancy in patients with malignant astrocytoma: a population-based study.Biosci Rep. 2019 Jun 14;39(6):BSR20181968. doi: 10.1042/BSR20181968. Print 2019 Jun 28. Biosci Rep. 2019. PMID: 31138756 Free PMC article.
-
Congress of Neurological Surgeons systematic review and evidence-based guidelines for the role of surgery in the management of patients with diffuse low grade glioma: update.J Neurooncol. 2025 Mar;172(1):99-152. doi: 10.1007/s11060-024-04871-4. Epub 2025 Jan 13. J Neurooncol. 2025. PMID: 39806106
-
Clinical and immunological correlates of long term survival in glioblastoma.Contemp Oncol (Pozn). 2018 Mar;22(1A):81-85. doi: 10.5114/wo.2018.73893. Epub 2018 Mar 5. Contemp Oncol (Pozn). 2018. PMID: 29628799 Free PMC article. Review.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical